尽管该公司报告季度亏损,但Apellis制药公司内部人员出售了大量股票。 Apellis Pharmaceuticals insiders sold significant stock despite the company reporting a quarterly loss.

包括CFO Timothy Sullivan和CEO Cedric Francois在内的Apellis制药公司内幕人士最近出售了相当一部分公司股票,将其所有权减少了近2%。 Apellis Pharmaceuticals insiders, including CFO Timothy Sullivan and CEO Cedric Francois, recently sold significant portions of their company stock, reducing their ownership by nearly 2%. 该股上涨 0.19 美元至 30.13 美元，尽管该公司报告上个季度每股亏损 0.46 美元，低于分析师的预期。 The stock is up $0.19 to $30.13, despite the company reporting a loss of $0.46 per share in its last quarter, missing analyst estimates. 机构投资者拥有96.29%的股票,该公司的市场上限为37.5亿美元。 Institutional investors own 96.29% of the stock, and the company's market cap is $3.75 billion. 分析师有好坏参半的审查,一致的“机动购买”评级和46.71美元的价格目标。 Analysts have mixed reviews, with a consensus "Moderate Buy" rating and a price target of $46.71.